Autophagy-inhibiting biomimetic nanodrugs enhance photothermal therapy and boost antitumor immunity. (26th January 2022)

• Record Type: Journal Article
• Authors: Huang, Pei-Ying; Zhu, Yin-Yin; Zhong, Hao; Chen, Pei-Ling; Shi, Qun-Ying; Chen, Jiao-Yu; Lai, Jin-Mei; Tu, Ying-Feng; Liu, Shu-Wen; Liu, Li-Han
• Is Part Of: Biomaterials science. Volume 10:Number 5(2022)
• Page Start: 1267
• Page End: 1280
• Publication Date: 2022-01-26
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d1bm01888d
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : We fabricated ICGCQ@RCm nanoparticles to ablate tumors effectively under mild-temperature PTT by inhibiting protective autophagy and exerting strong immunogenic cell death. Abstract : The instinctive protective stress responses of tumor cells hamper low-temperature photothermal therapy (LTPTT), resulting in tumor recurrence and metastasis. The rapid blood clearance and low-efficiency tumor enrichment of nanomedicines also decrease the efficacy of LTPTT. In this study, we fabricated coassembled photothermal agents (indocyanine green, ICG) and autophagy inhibitors (chloroquine, CQ) and red blood cell and cancer cell hybrid membrane (RCm)-camouflaged ICGCQ@RCm nanoparticles (ICGCQ@RCm NPs) to enhance tumor LTPTT. The ICGCQ@RCm NPs exhibited prolonged blood drug circulation and markedly enhanced drug accumulation in tumor tissues. The ICGCQ@RCm NPs reduced the thermal tolerance of tumor cells to sensitize ICG-mediated LTPTT by inhibiting protective autophagy. The ICGCQ@RCm NPs exerted strong immunogenic cell death (ICD) after efficient LTPTT to activate antitumor immunity. In addition, ICGCQ@RCms optimized the therapeutic efficacy by imaging-guided LTPTT, taking advantage of the near-infrared (NIR) fluorescence of ICG. Consequently, the ICGCQ@RCm NPs effectively inhibited tumors under mild LTPTT, significantly suppressed tumor metastasis and prolonged the survival time of tumor-bearing mice. Furthermore, the ICGCQ@RCm NPs showed high biosafety in vitro and in vivo . The ICGCQ@RCm NPs demonstrated tumor-targeting and imaging-guided autophagy inhibition-sensitized LTPTT using two Food and Drug Administration (FDA)-approved drugs, which have great potential for clinical application.